We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Exiqon's miRCURY LNA™ microRNA Array Product Line Selected as Preferred Platform by Multinational Company

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Exiqon A/S has announced that Dr. Alain Sewer, Phillip Morris International, R&D, Neuchatel, Switzerland, has presented data from a comprehensive validation study of the miRCURY LNA™ microRNA Array product line.

Dr. Sewer's data demonstrate that the LNA™-enhanced capture probes secure specific detection of microRNAs in complex samples. The study concludes that Exiqon's miRCURY LNA™ microRNA Array platform outperforms similar products provided by a main competitor.

Exiqon's microRNA arrays feature Tm-normalized, LNA™-enhanced capture probes, designed by advanced bioinformatics algorithms for specificity and sensitivity for all microRNAs in more than 100 different species.

The miRCURY LNA™ microRNA Array product line includes the miRCURY LNA™ microRNA Arrays, miRCURY LNA™ microRNA Power Labeling Kits and the miRCURY LNA™ microRNA Array Analysis Software. The products are provided with protocols for a number of different instrument platforms.

”We are always pleased when a major international customer publishes the conclusions from their internal validation studies. In this publication, it is demonstrated that Exiqon's products are superior in terms of sensitivity and specificity which represent the most important values for our customers”, said Henrik M. Pfundheller, VP Sales & Marketing at Exiqon.